Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIxico Regulatory News (IXI)

Share Price Information for Ixico (IXI)

Share Price is delayed by 15 minutes
Get Live Data
8.65    0.00 (0.00%)
Bid:
8.30
Ask:
9.00
Spread: 0.70 (8.434%)
Market Cap: £18.86m
IXI Live PriceLast checked at - London Stock Exchange

Intraday Ixico Share Chart

Total Voting Rights

4 Jan 2011 14:01

RNS Number : 8776Y
Phytopharm PLC
04 January 2011
 

 

4 January 2011

 

In accordance with the FSA's Disclosure and Transparency Rules sourcebook transitional provision 6, Phytopharm plc ("Phytopharm") hereby notifies the market of the following:

Phytopharm's issued share capital at 31 December 2010 consisted of 346,715,996 ordinary shares with voting rights. The Company did not, at that date, hold any shares in Treasury, and therefore the total number of ordinary shares in the Company with voting rights was 346,715,996.

The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Phytopharm plc under the FSA's Disclosure and Transparency Rules.

 

Zoe McGowanCompany Secretary

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TVRSSUFDLFFSELF
Date   Source Headline
25th May 20217:00 amRNSHalf yearly report to 31 March 2021
20th May 20217:00 amRNSPhase II Alzheimer’s disease contract award
19th May 20217:00 amRNSContract win for new neuroinflammatory disorder
11th May 20217:00 amRNSNotice of results
28th Apr 20217:00 amRNSContract win for new stroke study
26th Apr 20217:00 amRNSTrading update
19th Apr 20218:21 amRNSHolding(s) in Company
12th Apr 20214:00 pmRNSHolding(s) in Company
12th Apr 20217:00 amRNSInvestment in Ixico plc
1st Apr 20217:00 amRNSHolding(s) in Company
25th Mar 20219:14 amRNSPDMR Transaction
24th Mar 20219:05 amRNSSecond Price Monitoring Extn
24th Mar 20219:00 amRNSPrice Monitoring Extension
23rd Mar 20214:40 pmRNSSecond Price Monitoring Extn
23rd Mar 20214:35 pmRNSPrice Monitoring Extension
23rd Mar 20213:05 pmRNSHuntington’s disease Phase III contract updates
15th Mar 20214:41 pmRNSSecond Price Monitoring Extn
15th Mar 20214:35 pmRNSPrice Monitoring Extension
15th Mar 20212:06 pmRNSSecond Price Monitoring Extn
15th Mar 20212:00 pmRNSPrice Monitoring Extension
15th Mar 202111:06 amRNSSecond Price Monitoring Extn
15th Mar 202111:01 amRNSPrice Monitoring Extension
15th Mar 20217:00 amRNSCollaboration with Microsoft
10th Mar 20217:00 amRNSIXICO chosen for new Phase II AD study
2nd Mar 20217:00 amRNSIXICO selected by Cyclerion for a new AD study
1st Mar 20215:25 pmRNSExercise of Options; PDMR Dealing
1st Mar 20217:00 amRNSConference attendance and presentations
29th Jan 202110:19 amRNSPDMR Dealing
21st Jan 202111:05 amRNSResult of AGM
7th Jan 20217:00 amRNSIssue of Equity
24th Dec 20207:00 amRNSIXICO secures new contract for £3.4 million
14th Dec 202011:54 amRNSHolding(s) in Company
8th Dec 20207:00 amRNSIXICO contract with new large global pharma
3rd Dec 20202:06 pmRNSSecond Price Monitoring Extn
3rd Dec 20202:01 pmRNSPrice Monitoring Extension
2nd Dec 20207:00 amRNSFinancial Results for the year ended 30 Sept 2020
27th Nov 20207:00 amRNSIXICO announces £1.9 million new study award
9th Nov 20207:00 amRNSNotice of Results
3rd Nov 20207:00 amRNSAdditional Alzheimer’s disease contracts
22nd Oct 20207:00 amRNSFurther Huntington’s disease contracts
19th Oct 20207:00 amRNSIXICO to Present at SCA & ARCA Global Conference
19th Oct 20207:00 amRNSTrading Update for year ended 30 September 2020
16th Oct 20207:00 amRNSIXICO and NYU Langone Health sign agreement
30th Sep 20202:05 pmRNSSecond Price Monitoring Extn
30th Sep 20202:00 pmRNSPrice Monitoring Extension
29th Sep 20207:00 amRNS>£2m contract extension win - Huntington’s disease
24th Sep 20207:00 amRNSCollaboration with TRACK-FA NeuroimagingConsortium
21st Sep 20207:00 amRNSIXICO selected to support Alzheimer’s trial
11th Sep 202010:36 amRNSHolding(s) in Company
26th Aug 202011:55 amRNSInvestor presentation

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.